TAIPEI, Taiwan, May 23, 2019 /PRNewswire/ — The possible correlation between autism spectrum disorder (ASD) and gut microbiota has long been explored. A recent study, published in《Nutrients》, shows that a specific probiotic supplementation composed of Lactobacillus plantarum PS128 (Psychobiotic PS128™, commercialized by Bened Biomedical Co., Ltd.) may significantly alleviate symptoms of Autism spectrum disorder (ASD) and Attention Deficit Hyperactivity Disorder (ADHD).

Bened Biomedical Co., Ltd.: Psychobiotic PS128(TM) found to be a potential solution for Autism Spectrum Disorder (ASD) and Attention Deficit Hyperactivity Disorder (ADHD)

The study titled “Effects of Lactobacillus plantarum PS128 on Children with Autism Spectrum Disorder in Taiwan: A Randomized, Double-Blind, Placebo-Controlled Trial” was conducted by Prof. Ying-Chieh Tsai of National Yang-Ming University and the ASD experts in Taiwan. It is the first study utilizing probiotics over a double-blind, randomized, parallel-group, placebo-controlled clinical trial for behavioral improvement in subjects with ASD, which sets a milestone in research on the relationship between autism and probiotics.

In this 4-week intervention study, a total of 80 boys with ASD aged 7-15 were included and randomized to receive either PS128 (30 billion CFU/capsule) or placebo with daily doses of 2 capsules. The results showed that PS128 significantly ameliorated opposition and defiance behaviors. In addition, the total score of the questionnaires for ADHD and oppositional defiant disorder, SNAP-IV, for younger children (aged 7-12) improved significantly compared with the placebo group.

Autism spectrum disorder (ASD) is a developmental disorder that affects communication and social behaviors. According to the WHO, it is estimated that 1 in 160 children worldwide suffer from ASD, with the US more than doubling that ratio at 1 in 59 children instead. While ASD has been so prevalent, there have been no effective cures to date; early intervention has been the main treatment for children with developmental disorders. Recent animal studies have also found that specific probiotic strain can regulate brain hormones and improve symptoms of autism.

According to Prof. Ying-Chieh Tsai, two further clinical studies investigating the effects of Psychobiotic PS128™ on children with ASD are also underway. In Taiwan, “Psychophysiological effects of Lactobacillus plantarum PS128 in preschool children with autism spectrum disorder: a randomized, placebo-controlled trial” including preschool children with ASD was conducted in a teaching hospital in Taipei. And “The effects of probiotics and oxytocin nasal spray on social behaviors of ASD children- a pilot study” was an international collaborative study with the Massachusetts General Hospital.

Besides the successful ASD and ADHD studies, there have been several other clinical studies underway for PS128 targeting Central Nervous System (CNS) disorders such as Parkinson’s disease, depression, anxiety, Tourette syndrome, etc.

Reference: “Effects of Lactobacillus plantarum PS128 on Children with Autism Spectrum Disorder in Taiwan: A Randomized, Double-Blind, Placebo-Controlled Trial.” Nutrients, 2019 Apr 11;11(4), https://www.ncbi.nlm.nih.gov/pubmed/30979038

ABOUT Psychobiotic PS128™

Psychobiotic PS128™, the winner of “Probiotic Product of the Year” for the 2018 NutraIngredients-Asia Awards, is a novel psychobiotic that can modulate microbiota-gut-brain axis. As proven in the lab research and scientific publications, daily consumption of PS128™ can increase the concentration of dopamine and serotonin in key brain areas such as the prefrontal cortex or hippocampus. PS128™ is proven effective in preventing, alleviating and treating mental and movement disorders including autism, depression, anxiety, insomnia, IBS, Parkinson’s disease, etc. The first PS128™ product was commercialized in 2015 by Bened Biomedical Co., Ltd. and is now available as a dietary supplement in more than 15 countries in the world. 

Photo – https://photos.prnasia.com/prnh/20190523/2471733-1

Source: Bened Biomedical Co., Ltd.

HANGZHOU, China, May 21, 2019 /PRNewswire/ — China is a pioneer when it comes to e-commerce, and Alibaba is the country’s biggest platform, offering everything from clothes, furniture, electronics to food, cars and home products. Now, for the first time, Novozymes’ enzymes are available online through Alibaba’s platform for industrial products, 1688.com.

Novozymes opens online store on Alibaba

“We want to be a front runner in providing biological solutions online as well as offline. By partnering with Alibaba, we will get even closer to our end-customers, address local market needs faster and explore new application opportunities,” says Thomas Videbaek, COO and Executive Vice President, Novozymes.   

1688.com is home to more than ten million enterprises with 12 million daily visitors, and it has become a go-to place for business-to-business transactions.

“Novozymes is a world leader in biological innovation and the first multinational company to partner with 1688.com in the industrial biotechnology industry,” says Mr. Wang Hai, Vice President of Alibaba. “The launching of its flagship store will enrich the platform’s supply sources and serve millions of small and medium-sized Chinese enterprises with the most cutting-edge biological solutions.”

Add to cart
The Novozymes flagship store is currently offering end-customers nine enzyme products within food, professional cleaning and wastewater application areas. These are some of the company’s most popular products, and more will be added at a later stage.

“Biological solutions have a great potential in supporting sustainable development, and we hope to facilitate China’s green development and urbanization process through the exploration and trial of a digital business model,” Thomas Videbaek explains.

Photo – https://photos.prnasia.com/prnh/20190521/2473429-1
Logo – http://photos.prnasia.com/prnh/20160930/0861610134LOGO

The two diabetes device companies plan to launch CGM systems beginning in 2020

MALVERN, Pennsylvania, May 22, 2019 /PRNewswire/ — LifeScan, a world leader in blood glucose monitoring and maker of the iconic OneTouch® brand, today announced it has entered into an exclusive agreement with Sanvita Medical, LLC, to market continuous glucose monitoring (CGM) sensors. Sanvita Medical is a subsidiary of Nova Biomedical Corporation, a world leader focused on accuracy and dependability in advanced technology blood testing analyzers and blood glucose monitoring.

Through this collaboration, the companies plan to launch CGM systems in North America and select countries in Europe as early as mid-next year and then expand into other markets around the world. The new CGM products will integrate with LifeScan’s OneTouch Reveal® digital portfolio, including the OneTouch Reveal® app.

“There is a huge unmet need in diabetes management, and as a world leader in diabetes care we are excited to collaborate with Sanvita to help patients address that need with CGM technologies designed specifically with their concerns and goals in mind,” says Valerie Asbury, LifeScan President and CEO.  “For LifeScan, this is a natural extension of our vision to create a world without limits for people with diabetes and a reinforcement of our unwavering commitment to diabetes care.”

As a global leader in blood glucose monitoring and test strip manufacturing, the addition of CGM to LifeScan’s product portfolio is part of the company’s expansion and growth plans. The company has a long history of manufacturing and marketing blood glucose monitoring systems defined by simplicity, accuracy, and trust, including blood glucose meters, testing strips, lancets, point-of-care systems, and integrated digital solutions. “Soon we will be able to offer the spectrum of diabetes monitoring solutions—from our blood glucose monitoring systems to our digital products to CGM technologies with Sanvita,” Asbury says.

About LifeScan
With a vision to create a world without limits for people with diabetes, LifeScan is a world leader in blood glucose monitoring – globally more than 20 million people depend on OneTouch brand products to help them manage their diabetes. For over 35 years, LifeScan has had an unwavering commitment to improving the quality of life for people with diabetes by developing products defined by simplicity, accuracy, and trust. For more information, visit www.LifeScan.com and www.OneTouch.com.

Logo – https://mma.prnewswire.com/media/749088/Lifescan_Logo.jpg

Source: Lifescan, Inc.

WESTWOOD, Massachusetts, May 21, 2019 /PRNewswire/ — Surgical Specialties Corporation (SSC) announced today the launch of Caliber Ophthalmics, a new business division. Caliber Ophthalmics combines SSC’s Sharpoint™ brand, which has earned a trusted reputation serving ophthalmic surgeons for over 50 years, with its two recent ophthalmic acquisitions, Unique Technologies, Inc. and VPM Surgical, Inc.

To lead the Caliber Ophthalmics Division, SSC has named Yong Sun, General Manager Ophthalmology and Vice President, International Sales.  Mr. Sun has over 20 years of experience in the medical device and life science industries. He has held leadership roles in general management and commercial operations with Harvard Bioscience, Beaver-Visitec International (BVI), BD Medical Ophthalmics and Booz & Company. Mr. Sun holds an MBA from MIT’s Sloan School of Management.

Best known in the ophthalmic market for Sharpoint microsurgical knives and surgical sutures, SSC has specialized in the design and manufacture of high-performance surgical knives and wound closure products since 1969. The Company’s products are sold globally in more than ninety countries.  With the addition of Unique Technologies and VPM Surgical, the Company significantly expands its development and manufacturing expertise in ophthalmic blades and cutting instrumentation, and plans to add an ophthalmology manufacturing and engineering center of excellence in Pennsylvania.

“We are at an important inflection point in the ophthalmic industry with an expanding global economy and an increasing aging population,” said Dan Croteau, CEO of Surgical Specialties. “There has been remarkable technology advancement in eye care and tremendous growth in eye surgeries. We created the Caliber Ophthalmics Division to focus on the growing needs of  ophthalmic customers around the world.”

Mr. Croteau continued, “Caliber Ophthalmics brings together a unique and strong legacy of delivering quality, performance and innovation at competitive costs. With Yong Sun leading this new division, we are well positioned to not only deliver continued innovation and quality in our existing product lines, but have additional expertise that will allow us to expand into other ophthalmic product categories.”

About Surgical Specialties

Surgical Specialties Corporation, headquartered in Westwood, MA, has developed and manufactured branded, private label, and OEM surgical instruments for over 50 years. Surgical Specialties Corporation offers one of the most comprehensive portfolios of blades and sutures available, including innovative products such as the Quill™ Knotless Tissue-Closure Device.  SSC is dedicated to exceeding the needs of the specialty surgery market, maintaining trusted partnerships in the dental, ophthalmic, plastic surgery, dermatology, orthopedics, urology, microsurgery, veterinary and trauma specialties.  Visit us at www.surgicalspecialties.com and www.caliberophthalmics.com.

Media contact:
Matt Bastardi
SVP Commercial & Strategy
Surgical Specialties Corporation
mbastardi@surgicalspecialties.com

Logo – https://mma.prnewswire.com/media/326014/Surgical_Specialties_Corporation_Logo.jpg

SYDNEY, May 20, 2019 /PRNewswire/ — Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to announce that it has entered into a collaboration with the Alliance for Clinical Trials in Oncology Foundation (Alliance), a US-based cancer research network sponsored by the National Cancer Institute. Alliance will launch a multi-centre phase II study to investigate the potential use of Kazia’s investigational new drug, GDC-0084, alongside several other targeted cancer therapies, in the treatment of brain metastases (cancer that has spread to the brain).

“Brain metastases truly represent an unmet clinical need,” said Priscilla Brastianos, MD, Principal Investigator of the study, and Assistant Professor of Medicine at Harvard Medical School. “We urgently need to find better treatment options for these patients. We hope this study will help us identify a new treatment paradigm.” Dr Brastianos is also an Assistant Physician in Medicine in the Department of Hematology/Oncology at Massachusetts General Hospital. Her research interests focus on metastatic brain cancer, and she has been extensively published in this field. Dr Brastianos will be joined on the study Steering Committee by distinguished expert clinicians from leading centres across the United States.

Key Points

• Alliance will initiate an open-label phase II study in patients with brain metastases.
• Depending on the genetic profile of their tumor, patients will be allocated to receive either abemaciclib (Eli Lilly), entrectinib (Genentech), or GDC-0084 (Kazia Therapeutics).
• The trial is expected to recruit up to 150 patients in multiple centers across the US.
• The trial will be led by Alliance, with Kazia providing support including study drug and a financial grant.
• Initiation of this study brings the total number of ongoing clinical trials with GDC-0084 to four, each in different forms of brain cancer.

Up to 30% of patients with metastatic cancer will develop secondary tumors (metastases) in the brain, and it is estimated that there are approximately 200,000 new cases of brain metastases each year in the United States alone. Treatment options remain limited, and average survival of patients with brain metastases ranges from 3 to 27 months, depending on factors such as the location of the original tumor.

It is increasingly recognized that cancer is a complex disease, in which tumors in a similar location (e.g. breast, lung) may respond very differently to treatment. An important factor in this is the genetic profile of the tumor. Clinical studies have begun to focus on carefully allocating patients to treatment on basis of this genetic profile, an approach which is sometimes referred to as ‘precision medicine’ or ‘personalized medicine’. The Alliance study is an example of this approach.

The Alliance study, also known as A071701, is expected to recruit up to 150 patients in total, all of whom will have cancer that has spread to the brain. Only patients with a genetic alteration in the PI3K pathway will receive GDC-0084, and it is expected that approximately one third of the total patients will be in this group. Patients with other genetic mutations will be allocated to receive either abemaciclib, a CDK inhibitor, also known as Verzenio™, that is manufactured by Eli Lilly and has been approved by FDA for the treatment of certain forms of breast cancer, or entrectinib, a Trk/ALK inhibitor manufactured by Genentech, which has not yet been approved by FDA.

Dr James Garner, Chief Executive Officer of Kazia Therapeutics commented, “The Alliance study is a ground-breaking research project that aims to investigate several experimental drugs in a single clinical study. Patients will be allocated to treatment depending on their tumor’s individual genetic signature, and patients with a mutation affecting the PI3K pathway will be eligible to receive GDC-0084. This kind of approach is very much the future of cancer treatment. We are delighted that GDC-0084 has been selected and we are excited to see this study move forward.”

The initiation of the study brings to four the number of ongoing clinical trials with GDC-0084:

It is expected that the study will take approximately two years to complete. Kazia will provide support, including a financial grant to defray a portion of the costs. The study will be conducted under an ‘investigator IND’ with the US FDA, in which the primary regulatory responsibilities for the study will be assumed by Alliance. Implementation of the study is conditional upon approval from applicable Institutional Review Boards, and completion of contractual formalities, and these matters have not yet been finalised. It is expected that the study will begin recruitment in the second half of calendar 2019.

About Kazia Therapeutics Limited

Kazia Therapeutics Limited (ASX: KZA, NASDAQ: KZIA) is an innovative oncology-focused biotechnology company, based in Sydney, Australia. Our pipeline includes two clinical-stage drug development candidates, and we are working to develop therapies across a range of oncology indications.

Our lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma multiforme, the most common and most aggressive form of primary brain cancer in adults. Licensed from Genentech in late 2016, GDC0084 entered a phase II clinical trial in 2018. Initial safety data was released in May 2019, and efficacy data is expected in 2H 2019. GDC-0084 was granted orphan designation for glioblastoma by the US FDA in February 2018.

TRX-E-002-1 (Cantrixil), is a third-generation benzopyran molecule with activity against cancer stem cells, and is being developed to treat ovarian cancer. TRX-E-002-1 is currently undergoing a phase I clinical trial in Australia and the United States. Initial data was presented at the AACR annual conference in April 2019 and the study remains ongoing. Cantrixil was granted orphan designation for ovarian cancer by the US FDA in April 2015.

About the Alliance for Clinical Trials in Oncology

The Alliance for Clinical Trials in Oncology (Alliance) is a clinical trials network that involves approximately 10,000 physicians across the United States and Canada. The Alliance seeks to reduce the impact of cancer on people by uniting a broad community of scientists and clinicians from many disciplines, committed to discovering, validating and disseminating effective strategies for the prevention and treatment of cancer. It is part of the National Clinical Trials Network (NCTN) sponsored by the US National Cancer Institute (NCI).

Logo – https://photos.prnasia.com/prnh/20171120/1996749-1LOGO

Fully comprehensive assistance service for complex international deployment

LONDON, May 15, 2019 /PRNewswire/ — Collinson, an expert in global traveller assistance, has further enhanced its medical assistance capability through a partnership with Aspen Medical, an Australian-owned global healthcare leader providing remote medical solutions across a range of sectors.

Aspen Medical provides innovative and tailored healthcare services, from the provision of a single paramedic to a full spectrum solution involving a multi-disciplinary team of healthcare professionals. Further services include, ambulances, medical facilities, equipment, consumables, pharmacy products and aero-medical evacuation services (AME), including the company’s own strategically-positioned clinics and aviation assets.

Often working in locations that are remote, challenging or under-resourced, its multi award-winning solutions provide clients with world-class healthcare services in any setting. The partnership will enable Collinson to extend its assistance reach and help customers to access quality medical services in locations where existing medical infrastructure is lacking. By augmenting Aspen Medical’s ground-level capability with the wider Collinson global medical and evacuation network and its 24/7 always-on medical and security operations centres, the partnership will create a fully comprehensive assistance service for complex international deployments.

Aspen Medical’s services also include managing environmental and public health projects, medical training and consultancy, providing occupational health and supporting major sporting events and conferences that need dedicated clinical support.

Scott Sunderman, Head of Assistance at Collinson, commented: “Aspen Medical is renowned for its high-profile contracts with defence, mining, oil and gas, government and humanitarian organisations. From running trauma hospitals in Mosul, Iraq, for the WHO or staffing and managing a UN facility for its personnel in Somalia, through to supporting the UK, US, Australian and New Zealand governments on the construction and management of Ebola Treatment facilities in Sierra Leone and Liberia, our partnership with Aspen Medical truly gives us a global healthcare reach and access to expertise unparalleled in the market.

“This experience will be vital as we broaden our global medical assistance and travel risk management services to ensure clients have the best possible protection, wherever they may be located.”

This strategic alliance further enhances Collinson’s new 24/7/365 integrated travel risk management solution in partnership with global risk and security consultancy, Drum Cussac, as well as the appointment of its new Global Medical Director, Simon Worrell.

Glenn Keys, Executive Chairman and co-founder of Aspen Medical, said: “Collinson is recognised globally for providing an exceptional medical assistance service. This partnership with Collinson further develops Aspen Medical’s global capability with an integrated travel risk management solution. When combined with Drum Cussac’s expertise, their global assistance App, security alerts, location tracking and monitoring, together we are delivering a very powerful new capability in the market for those seeking assistance in times of need.”

Editors notes:

Collinson is one of the largest independent medical assistance companies with more than 35 years’ experience. Its assistance platforms in the UK, Ireland and South Africa provide services 24/7/365 to a number of insurance markets and corporate entities. Collinson receives over 1.2 million calls from customers around the world and conducts over 3,000 repatriations and evacuations annually.

Our 24/7/365 global resources and expertise provide a comprehensive suite of travel risk services for mobile employees that help organisations manage their duty of care towards staff that operate away from their home country. Whether you require a full travel risk management programme for your employees, a customised assistance solution, crisis management planning or specific analysis and support for remote site operations, Collinson can build a solution that enables you to protect your most valuable assets, as well as protecting your organisational risk.

Clients include Air France KLM, American Express, British Airways, Cathay Pacific, Diners Club, Easy Jet, Mastercard, Saga, RSA, Visa and Vhi.

Aspen Medical is an Australian-owned, multi-award winning, global provider of innovative healthcare solutions across a diverse range of clients in the Defence, Mining, Oil and Gas, Government and Humanitarian sectors. We are a world leader in the delivery of healthcare solutions in any setting, particularly those that are remote, challenging or under-resourced.

We offer our clients a tailored and flexible service wherever it is needed – from a single paramedic to a full-spectrum solution involving a multidisciplinary team of healthcare professionals, ambulances, medical facilities, equipment, consumables, pharmacy products, procedures, mobile health and surgical solutions and aero-medical evacuation services including the company’s own aviation assets.

Our competitive advantage lies in superior project management and the quality of our team. We pride ourselves on a customer-centric approach and a ‘can do’ attitude. Today, we operate across Australia, the Pacific, the US, Europe, Africa and the Gulf Region and we employ more than 2,000 dedicated, experienced and highly-trained professionals.

CHENNAI, India, May 15, 2019 /PRNewswire/ — In a first-ever milestone in cancer treatment in India, the Apollo Proton Cancer Center (APCC) in Chennai has successfully performed Total Marrow Irradiation (TMI) as a conditioning protocol prior to Bone Marrow Transplant.

(From Left to Right) Dr. Dayananda Shamurailatpam, Head Department of Medical Physics, Apollo Hospitals, Dr. Rakesh Jalali,Medical Director and Head – Radiation Oncology , Apollo Proton Cancer Centre, Dr . Jose M Easow, Consultant Medical Oncology and Hematology In – charge of BMT Unit, Apollo Cancer Speciality Hospital, Patient Ms.Fatima (35) Oman, Dr . Prathap C Reddy,Executive Chairman, Apollo Hospitals Group, Dr. Preetha Reddy, Vice Chairperson, Apollo Hospitals Group, Dr. Srinivas Chilukuri – Senior Consultant Radiation Oncology, Dr . Sapna Nangia, Senior Consultant, Radiation Oncology at Apollo Proton Cancer Centre, Chennai

Dr. Preetha Reddy, Vice Chairperson, Apollo Hospitals Group said, “The Apollo Proton Cancer Centre has opened new frontiers in cancer care and it is a proud moment today, just a few months after the launch, to see the APCC achieve this significant landmark for the first time in the country. This achievement validates our investment in the APCC in bringing this best and latest medical technology to India. We are sure that the future will see the APCC achieve many more milestones and take the battle against cancer forward not just for patients in India but also from South East Asia.”

A 35-year-old nurse from Oman underwent the procedure at South East Asia’s first Proton Therapy Center. She was diagnosed with Chronic Myeloid Leukemia (CML) with mixed phenotypic acute leukemia. After the diagnosis, she was referred to Apollo Hospitals for Bone Marrow Transplant. The doctors at Apollo decided to proceed with Total Marrow Irradiation based conditioning for the transplant.

“The patient was admitted last month and after detailed diagnosis, we decided to proceed with Total Marrow Irradiation followed by chemo and peripheral blood stem cell transplantation. The patient’s brother turned out to be a full-matched donor. The patient has responded very well to the treatment and is getting ready for discharge,” said Dr. Jose M Easow.

The patient, Ms. Fatima, said, “I am grateful to the Oman Government, Oman for selecting and sending me to Apollo Hospitals, Chennai which is the best hospital to treat cancer in India. I was advised BMT, and my brother was selected as a donor. I was admitted on April 5^th and felt at home from Day One. As a nurse, I know how radiation therapy can affect a patient’s normal life due to side effects. The Total Marrow Irradiation procedure done for me was different and it has saved my life with much less side-effects. The procedure made me more confident and positive.”

“With modern radiation technology, it is now possible to deliver Total Marrow Irradiation (TMI) which spares the normal organs from radiation induced damage,” said Dr. Srinivas Chilukuri, Senior Consultant Radiation Oncology.

CHENGDU, China, May 16, 2019 /PRNewswire/ — WuXi Biologics (“WuXi Bio”) (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, announced that the construction of a new 1.3 million sq. ft. integrated manufacturing center for innovative biologics has commenced in Chengdu, one of the largest cities in Southwest China. The facility will house the 12^th drug substance manufacturing facility (MFG12) of WuXi Biologics.

WuXi Biologics Integrated Manufacturing Center for Innovative Biologics in Chengdu (Preview)

This new integrated manufacturing center will include drug development and commercial manufacturing facilities with initial bioreactor capacity of 48,000 L. As the first biologics company in China passing both U.S. FDA and EMA GMP inspections, WuXi Biologics will apply its extensive expertise as well as a well-established quality system that conforms to the highest international standards at this new integrated manufacturing center. The new site will enable more global partners, create more jobs for local talents, stimulate high growth of the biologics industry in Chengdu as well as accelerate the biologics ecosystem in Southwest China.

“We are quite excited to commence this new integrated manufacturing center, the largest biologics manufacturing facility in Southwest China,” said Dr. Chris Chen, CEO of WuXi Biologics. “Supported by 205 ongoing biologics projects using WuXi Biologics’ open-access and proprietary platforms as well as our unique manufacturing paradigm of ‘Global Dual Sourcing within WuXi Bio’, we will continue to expand manufacturing capacity, based on our portfolio needs, to provide a robust and premier global supply chain that can enable our partners and benefit patients worldwide.”

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and strong value proposition to our global clients. As of December 31, 2018, there were a total of 205 integrated projects, including 97 projects in pre-clinical development stage, 94 projects in early-phase (phase I and II) clinical development, 13 projects in late-phase (phase III) development and 1 project in commercial manufacturing. With total estimated capacity of biopharmaceutical production planned in China, Ireland, Singapore and US reaching 220,000 liters by 2022, we will provide our biomanufacturing partners with a robust and premier-quality global supply chain network. For more information on WuXi Biologics, please visit www.wuxibiologics.com.

Photo – https://photos.prnasia.com/prnh/20190516/2464420-1 

NEW DELHI, May 17, 2019 /PRNewswire/ — With the theme of ‘Promoting Inclusive Economic Development Through Sustainable Entrepreneurship’,15 top entrepreneurs and enterprises were recognized at the Asia Pacific Entrepreneurship Awards (APEA) 2019 held at Hotel Andaz Delhi Aerocity, India on 18 April 2019. Organized by Enterprise Asia, the leading non-governmental organization for entrepreneurship in Asia, APEA is a regional awards program which aims to recognize Asia’s outstanding entrepreneurs and enterprises for demonstrating sustainable growth, responsible leadership and operational excellence.

Mr. Ashish Khemka, Chairman and Managing Director of AMN Life Science receiving the Asia Pacific Entrepreneurship Awards 2019 India under the Outstanding Category

Leading the list of winners was Mr. Ashish Khemka, Chairman and Managing Director of AMN Life Science Pvt. Ltd. (AMN Life) who received the award under the Outstanding Category.

Incorporated in 2003, AMN Life is a leading Pharmaceutical manufacturing and export house offering a plethora of brands covering a wide range of therapies from both acute and chronic segments. These formulations cater to the therapeutic needs for allergic disorder, bacterial and fungal infections, malaria, erectile dysfunction, Diabetes and Cardio-vascular diseases to name a few. Amihepa, Renoket, Avam, S-Valapro, Suncetin, Asita and Amcort are few of the AMN Life brands that command a leadership position in the covered markets.

Prior to venturing into the pharmaceutical industry, Mr. Ashish joined Trans Freight Container Corporation Ltd. a 100% export oriented Marine Freight container manufacturing unit as a management trainee. With sheer dent of merit and enterprise, he gained expertise in the field and simultaneously acquired managerial and leadership skills, and rapidly rose to the level of COO within a year.

Throughout his professional and entrepreneurial career, Mr. Ashish managed to acquire a fine grasp of the pharmaceutical market and established credibility and reliability in his dealings. This has contributed to the success of AMN Life. Passionate about AMN Life, he ensures that all departments within the company upholds professional standards. His leadership quality holds great promise and his employees are extremely supportive of his vision for the Company.

Being a results-oriented entrepreneur, Mr. Ashish is driven to manage costs and establish strategic mutually beneficial partnerships and relationships with users, vendors and service providers. He is also adept in creating strategic alliances with industry leaders to effectively align with and support AMN Life’s key business initiatives. Besides, he excels at building and retaining high performance teams by hiring, developing and motivating skilled professionals.

Under the leadership of Mr. Ashish, the exports of AMN Life showed a year-on-year growth of more than 100% in financial year 2007 and bagged the Indian Exporters’ Excellence Award. Continuing its growth trajectory over the years, the Company bagged SME business excellence Awards and leading SMEs of India 2016 in the Pharmaceuticals sector.

Presented in 25 countries, AMN Life’s success holds a dominant position in south East Asian markets, and is poised to grow its presence to almost 150 countries across the globe.

Mr. Ashish’s innovative entrepreneurial skill resulted in the acquisitions of ASA LIFE, Singapore in year 2018 and many more acquisitions are planned along with setting up offices worldwide. In the immediate future, AMN Life is poised to grow to achieve a dominating presence in the European union with provision for In-licencing and out – licencing opportunities. Today the Group boasts of more than 10 Companies India and Overseas and registered the sales turnover of more than Rs. 250 Crore across the group companies.

The Entrepreneur strives to drive operational excellence in every department within his business. It is not an easy concept to quantify, and very difficult to explain in simple practical terms to operators of different departments, however, he managed to overcome these challenges.

Besides, Mr. Ashish always guides the team to justify and use cost-efficient technologies, to bring out top quality products that are economical and reliable. His innovation strategy involves streamlining an increasingly complex manufacturing system. This type of next-generation innovation wades through the growing sea of new ideas and emerges with the strategies that deliver a clear and focused value in the form of targeted Acquisitions and partnerships, personalized treatments, efficient outsourcing partners and properly integrated innovative technologies, but perhaps this statement has wider implications for today’s pharmaceutical industry.

Mr. Ashish believes that, the practice of cranking out rapid-fire innovation in the form of new molecules with the hopes of finding the next blockbuster is being replaced by targeted innovation strategies that demonstrate actual patient value and reach that can be duplicated across an enterprise.

Under his leadership, AMN Life is currently eying the EU certification along with highly professional team of 200 plus professionals and available to consider new alliance opportunities in the uncontested zones of in In-licensing, co-promotion, revenue sharing and carved partnership opportunities.

Mr. Ashish has also undertaken challenging green initiatives, which is reflected throughout AMN Life’s Supply Chain. The issue of Pharmaceuticals in the Environment has garnered plenty of media attention, mostly negative in the past several years. Most of the concern with drugs in the environment revolves around consumers who either excrete un-metabolized active ingredients or dispose of unused medications into sewage systems. Under his leadership, AMN Life is able to ensure complete deactivation of waste residues by using alkaline solution before it is being sent to centralized insemination.

About Enterprise Asia

Enterprise Asia is a non-governmental organization in pursuit of creating an Asia that is rich in entrepreneurship as an engine towards sustainable and progressive economic and social development within a world of economic equality. Its two pillars of existence are investment in people and responsible entrepreneurship. Enterprise Asia works with governments, NGOs and other organizations to promote competitiveness and entrepreneurial development, in uplifting the economic status of people across Asia and in ensuring a legacy of hope, innovation and courage for the future generation. For further information, visit www.enterpriseasia.org.

About Asia Pacific Entrepreneurship Awards

Launched in 2007, the Asia Pacific Entrepreneurship Awards is the region’s most prestigious awards for outstanding entrepreneurship, continuous innovation and sustainable leadership. The Awards provide a platform for companies and governments to recognize entrepreneurial excellence, hence spurring greater innovation, fair business practices and growth in entrepreneurship. As a regional award, it groups together leading entrepreneurs as a powerful voice for entrepreneurship and serves as a by-invitation only networking powerhouse. The program has grown to encompass 14 countries and markets all over Asia. For further information, visit www.apea.asia.

Photo – https://photos.prnasia.com/prnh/20190517/2470505-1